IMUGENE
Developing Cancer Immunotherapies

ASX:IMU

Investor Presentation
September 2023

DEVELOPING CANCER IMMUNOTHERAPIES

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited

CASH POSITION

Imugene has one of the highest cash balance of ASX biotech

CASH BALANCE AS AT 30 JUNE 2023

Company	Ticker	Cash [A$'MM]
Imugene	IMU	153
Telix	TLX	132
Immutep	IMM	123
Mesoblast	MSB	106
Avita	AVH	56
Polynovo	PNV	47
Impedimed	IPD	46
Neuren	NEU	38
Immuron	IMC	17

- Pro-forma cash balance of $186m
- A$17 million in July/August relating to azer-cel acquisition
- Provides cash runway for approximately two years
- ~75% of overall spend on R&D in Fiscal Year 2023
- 15% on total spend on Operational Spend (SG&A) is very modest by industry standards for a clinical portfolio as deep as ours
- 10% Other costs including share-based payments

INVESTMENT HIGHLIGHTS

IMUGENE
Developing Cancer Immunotherapies

Market Capitalisation
As at 27 September 2023
A$358M

Cash Position
A$186M (Pro-forma)

6 Unique Assets

azer-cel
onCARlytics
CHECKvacc
HER-Vaxx
PD1-Vaxx
Vaxinia

*Multiple potential platform targets

- CF33-CD20
- PDL1-Vaxx
- TIGIT-Vaxx
- CTLA4-Vaxx
- LAG3-Vaxx
- TIM3-Vaxx

4 Platform Technologies

- Allo CAR T Cell Therapy IMUGENE
- onCARlytics IMUGENE
- CF33 Oncolytic Virus IMUGENE
- B Cell Immunotherapy IMUGENE

4 Scientific Collaborations

- Celularity
- Renovo
- Eureka
- Arovella

Disease Areas

Blood cancers
Breast (TNBC)
Lung (NSCLC)
Gastric
Gastroesophageal
Colorectal (CRC)
Melanoma
Head and Neck
Hepatocellular
Pancreatic
Glioblastoma (GBM)



7 FDA IND

Clinical Studies

	FDA IND
AZER-CEL Ph1b/2 registrational DLBCL	✓
IMPRINTER: Ph1 NSCLC	✓
CHECKvacc COH IST: Ph1 TNBC	✓
neoHERIZON: Ph2 Neoadjuvant Gastric Cancer	
nextHERIZON: Ph2 Metastatic Gastric Cancer	✓

	FDA IND
MAST: Ph1 Solid Tumors	✓
DOMINICA: Ph1 TNBC	✓
onCARlytics: Ph1 Solid Tumours	✓
neoPolem IST: Ph1 CRC	
HERIZON: Ph1b/2 First line Gastric Cancer	

2 Supply Agreements

- Merck KGaA
- Roche

FOUR UNIQUE PLATFORMS MAXIMIZE OPPORTUNITIES IN CANCER

IMUGENE
Developing Cancer Immunotherapies

Treatments that can be combined with and enhance outcomes of existing standards of care.



Allo CAR T Cell Therapy
IMUGENE

AZER-CEL CD19 ALLOGENEIC CAR T CELL THERAPY

EXECUTIVE SUMMARY

Allo CAR T Cell Therapy
IMUGENE

Imugene has licensed a near term potential registrational stage, off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Imugene can also use this drug to combine with its existing onCAR19 to treat solid tumors.

The transaction includes:

Exclusive world-wide license to the First in Class product known as azer-cel with over 84 patients treated in a Phase I trial, demonstrated safety and compelling efficacy
3 additional asset targets

Encouraging FDA guidance and feedback on manufacturing for a potential Fast to Market PHASE 2 registration trial.

Potential for first FDA approved Allogeneic CAR T

Completed drug material and manufacturing process

Manufacturing facility with a highly technically skilled and specialised work force

THE FUTURE OF CELL THERAPY IS OFF THE SHELF

Allo CAR T Cell Therapy
IMUGENE

Patients shouldn't have to wait for treatment

AUTOLOGOUS



- Limited patient access
- Long and complex manufacturing process and wait time (requires leukapheresis and bridging is often required)
- High manufacturing costs
- Variable potency

ALLOGENEIC



- Broad patient access
- Available on demand and off-the-shelf immediately (no leukapheresis and no bridging required)
- More efficient and cost-effective manufacturing
- Healthy donor cells engineered for potency and persistence

TOTAL BODY OF EVIDENCE

Allo CAR T Cell Therapy
IMUGENE

Azer-cel has meaningful Clinical Activity across B Cell Malignancies

84 patients treated with azer-cel

61

Non-Hodgkin lymphoma (NHL) Patients

58% ORR[1] | 41% CR[2]

+

23

B-Cell lymphoblastic leukaemia (B-ALL) Patients

61% ORR | 61% CR/CRi

All Doses / All LD* Regimens

1. ORR – Overall Response Rate
2. CR – Complete Response
*lymphodepletion
Note: Based on Patients Evaluable for Efficacy

AZER-CEL IS ACTIVE IN CAR T RELAPSED PATIENTS

Demonstrated high response rates and durability

Across All Subjects
All Doses / All LD Regimens

61
NHL Patients

18
Patients

CAR T Relapse Pts

83% ORR

61% CR Rate
55% DoR ≥ 6-months[1]

*Median duration in ≥ 6-month responders is 431 days

Azer-cel has the potential to provide new standard of care for this high-risk population with unmet need

Note: Based on Patients Evaluable for Efficacy
N=11 patients evaluable for > 6 months duration on response, 6 durable responders past 6 months or longer with 431 (> 1 year) median days on response; DoR measured from D0

CD19 AUTO CAR T RELAPSE MARKET IS LARGE AND GROWING

Allo CAR T Cell Therapy
IMUGENE

~85%

of patients continue to have CD19+ disease

In our prospective data, patients continue to have antigen positive disease

YESCARTA Breyanzi KYMRIAH® (tisagenlecleucel) Dispersion for IV infusion

60-65%

of patients currently treated with auto CD19 CAR T will relapse (fail)[2]

By 2025

Global CAR T relapse patient pool is expected to grow ~4x as auto CAR T drugs become the SOC in 2L+

Estimate total Global G8 markets to be ~18k patients per year[3]

Note: Retrospective Literature states that 12-28% of patients have antigen negative relapse (CD19-)

1. Precision Internal Clinical Data; 2. Estimated from ZUMA 1 and ZUMA 7 EFS rates; 3. G8 includes US, Japan, Canada and EU5 assuming equal access to CAR T therapies; market research, CancerMPact

PHASE 2 TRIAL ASSUMPTIONS (POTENTIAL REGISTRATIONAL/TO MARKET)

Potential registrational study (FDA approval) to start upon completion of the Phase 1B study H2 2024

Population: Auto CAR T failures in DLBCL patients

Positive formal and informal FDA guidance on the potential registrational study

~35+ sites in the U.S.: Phase IB trial currently conducted at Dana Farber, Moffit, MDACC, COH, Karmanos, U Minnesota, Cornell, Columbia

Drug product for Phase 1B confirmatory trial completed

Drug material manufactured in North Carolina at our facility

Dana-Farber Cancer Institute

MOFFITT CANCER CENTER

Masonic Cancer Center
University of Minnesota

The University of Texas MD Anderson Cancer Center

City of Hope

AZER-CEL OFFERS ONCARLYTICS AN IN-HOUSE COMBINATION APPROACH FOR SOLID TUMOURS

Allo CAR T Cell Therapy
IMUGENE

Enables Imugene to progress its own combination solution in multiple solid tumour indications

Strengthen current development of onCARlytics by adding an in house off the shelf CD19 CAR T

Enables and boosts Imugene's footprint in the blood cancer and continued solid tumour oncology markets

Combination treatment for solid tumours



CMC & MANUFACTURING

Fully GMP compliant

Allo CAR T Cell Therapy
IMUGENE

Manufacturing – 32,800 (17,300 manufacturing +15,500 expansion) sq ft facility in Durham, NC

GMP compliant / 3rd party audits completed with no findings

Turn-key solution ready for final registrational trial drug product supply

Robust and validated process for 84 patients dosed to date (optimized along the way)

Drug product for Phase 1B confirmatory trial completed

Experts transitioning to Imugene for continuity of drug manufacturing

AZER-CEL VALUE INFLECTION POINTS EXPECTED IN THE NEXT 12-18 MONTHS

Allo CAR T Cell Therapy
IMUGENE

Key Events

Q3, 2023 FDA Process 1.2 Drug Lot Release (validating Phase 2 registrational study drug)
Q3, 2023 FDA IND transferred to Imugene
Q4, 2023 First Patient in for Phase 1b Expansion
Q2, 2024 Patient recruitment status and completion of enrolment of Phase 1b
Q4, 2024 Phase 1b readout and FDA feedback on registrational study
Q4, 2024 Status on Site approval activity
Q1, 2025 First Patient Dosed on registrational Study



WHY IMUGENE?

IMUGENE
Developing Cancer Immunotherapies

Diverse asset portfolio with multiple shots on goal across four novel platforms

Experienced Management team*

Ongoing clinical trials in diverse solid tumours and blood cancers with multiple value inflection points

Robust cash runway with funding through key milestones

*Addition of Dr. Paul Woodard, Dr. John Byon and Dr. Brad Glover

MULTIPLE VALUE REALISATION PATHWAYS

IMUGENE
Developing Cancer Immunotherapies

Company acquisition

Partner with big pharma

License technologies separately

Develop / Commercialise independently

IMUGENE
Developing Cancer Immunotherapies

ASX:IMU

shareholderenquiries@imugene.com
imugene.com